These findings raise the possibility that p53-activating drugs, many of which are currently in clinical trials, may have unforeseen effects on macrophage susceptibility to HIV-1 infection, thus influencing the establishment of an HIV-1 reservoir in these cells. The gene discussed is TP53; the disease is HIV-1 infection.